Notwithstanding promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from managed care entities. These insurers are often creating obstacles to coverage, such as high cost restrictions and approval processes that restrict patient opportunit… Read More